Scientists at the Wellcome Sanger Institute have, for the first time, encoded a complete virus genome on a quantum computer. The team stored the genetic material of the hepatitis D virus on IBM's Heron processor with 156 qubits, improving on earlier attempts by at least one order of magnitude. The result answers a fundamental question of quantum biology: biological information of this complexity can indeed be mapped onto quantum hardware. For pharmaceutical drug discovery, which spends billions every year on clinical failures, a new chapter has begun.
Why the Scale Matters
A quantum computer represents data not in classical zeroes and ones but in qubits, which can occupy multiple states at once. This enables calculations where classical computers reach their limits: certain biochemical simulations, which would require classical systems to compute exponentially many states, could run on quantum hardware in minutes rather than decades. The prerequisite was previously unmet, because quantum systems did not have enough stable qubits to map biological molecules at sufficient complexity.
The hepatitis D virus is one of the smallest known human pathogens. Its genome spans 1,678 bases and is therefore well suited as a test case for current quantum hardware. Earlier attempts to translate biological sequences into quantum states failed on fragments of a few dozen bases. For comparison, the human genome contains roughly three billion base pairs. Today's breakthrough is a proof of concept on the smallest clinically relevant object, far from human genomics. But it proves the principle.
An International Contest as Driver
The result emerged from the Q4Bio Challenge organized by Wellcome Leap, a competition that pairs quantum hardware with concrete biological questions. Wellcome Leap is a funding arm of the London-based Wellcome Trust, investing in high-risk, high-potential research projects. Five of six teams in the final round used IBM quantum computers as their platform. The top prize of two million dollars went to Finnish startup Algorithmiq together with the Cleveland Clinic in Ohio. Algorithmiq develops quantum algorithms for drug discovery and demonstrated that its approach surpasses classical solutions in certain molecular simulation tasks. This is the threshold IBM calls Quantum Advantage.
IBM used the competition to document the practical deployment of its hardware in the life sciences. The competition fields spanned genomics, biomarker research, drug development and biochemistry. The Q4Bio Challenge establishes a new pattern: instead of synthetic benchmarks, quantum computers are measured against real scientific problems. The question shifts from the number of available qubits to what a system can actually solve.
What the Proof Means, and What It Does Not
IBM's Heron processor with 156 qubits is not yet a fault-tolerant system. In practice this means calculations can be distorted by qubit noise, which limits complex long-running simulations. Fault tolerance means combining multiple physical qubits into a robust logical qubit that detects and corrects its own errors. That technology is not yet mature for industrial applications. For pharmaceutical companies that want to simulate protein interactions for hours at a time, this is the real obstacle.
The economic case for deployment already holds on the path toward that goal. Of the roughly 2,000 to 3,000 compounds a pharmaceutical company tests per drug candidate, most fail on molecular properties that precise quantum simulation could predict. If quantum computers can avoid even a fraction of these failures, the savings run into billions. The path there leads through steps like today's: show that representation is possible before computation can be scaled. The genome encoding by the Wellcome Sanger Institute is the first such step.
Proteins, not just viruses, are where research interest really lies. Misfolded proteins cause Alzheimer's disease, Parkinson's and cancer. Google DeepMind's AlphaFold has already solved protein structure classically. The next step would be dynamic simulation: how a protein changes shape when a drug binds. For these calculations, quantum computers are theoretically ideal. But that requires systems that compute more fault-tolerantly than the Heron processor does today.
Context: Europe's Quantum Strategy
The Wellcome Sanger result arrives against a European quantum landscape on the move. Three days before publication, Germany's Federal Ministry of Education and Research launched the Quantum Computing Competition, a funding programme offering consortia up to 55 million euros if they build error-corrected quantum computers by 2030. Europe has lagged in the global comparison so far: IBM already operates systems with more than 1,000 qubits, and Google published the first evidence of Quantum Advantage with its Sycamore chip in 2019. Today's IBM result shows that Europe's gap can in part be bridged through targeted research partnerships with US hardware.
IBM has Quantum Advantage on its development roadmap for 2026, the point at which quantum computers surpass classical systems on concrete tasks. The Q4Bio Challenge is an attempt to demonstrate this transition on real scientific applications rather than synthetic benchmarks. Wellcome Leap is planning a second round of the competition. Whether larger genomes can be scaled on error-corrected systems depends on how IBM evolves its Heron processor over the coming months. On 14 April 2026, Germany at least laid the structural framework with the Quantum Computing Competition to bring European systems to that level.